Department of Diabetes, University Hospital Llandough, Cardiff, Wales, UK.
Diabetes Ther. 2012 Nov;3(1):1-8. doi: 10.1007/s13300-012-0001-z. Epub 2012 Feb 29.
Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone and an increased risk of bladder cancer. There is thus a growing focus on the risk-benefit profile of this agent and hence its potential role in the blood glucose-lowering treatment algorithm for people with type 2 diabetes. There are clear potential outcome benefits associated with pioglitazone. In this review, the authors focus on putting the true risk-benefit profile of pioglitazone into context based on critical appraisal of the currently available evidence.
吡格列酮是一种噻唑烷二酮类药物，可改善胰岛素敏感性，从而降低血糖。临床试验表明，吡格列酮可能具有心血管结局获益；然而，安全性担忧日益增加，最近的数据表明吡格列酮与膀胱癌风险增加之间存在关联。因此，人们越来越关注该药物的风险效益比及其在 2 型糖尿病患者血糖降低治疗方案中的潜在作用。吡格列酮具有明确的潜在获益。在这篇综述中，作者基于对现有证据的批判性评估，重点阐述了吡格列酮的真实风险效益比。
